Results 151 to 160 of about 40,951 (233)

Feasibility of multifrequency MR elastography of the seminal vesicles in healthy men, benign prostatic hyperplasia, and prostate cancer. [PDF]

Eur Radiol Exp
Davis KV, Thiess HM, Asbach P, Tiberi E, Denecke T, Hamm B, Gebauer B, Vogel-Claussen J, Sack I, Reiter R.   +9 more
europepmc   +1 more source

Modified water vapor thermal therapy for large-volume benign prostatic hyperplasia. [PDF]

BMC Urol
Lu Q, Zhu G, Liu J, Huang H, Zhang F, Qiu X, Xu L, Guo H.   +7 more
europepmc   +1 more source

Benign prostatic hyperplasia to HPIN to carcinoma; the impact of mast cells and VEGF. [PDF]

Diagn Pathol
Sivrikoz ON, Eroğlu A, Öztürk B, Öztop İ, Sanal SM.   +4 more
europepmc   +1 more source

Integrated management strategies for benign prostatic hyperplasia. [PDF]

Front Urol
Zhou Y, Luo Q, Wang R, Zheng D, Xiong Y, Zuo J, Wang S, Zhong L.   +7 more
europepmc   +1 more source

Airborne chloride exposure and benign prostatic hyperplasia risk. [PDF]

BMC Res Notes
Shi J, Phanumartwiwath A.
europepmc   +1 more source

Causal links of 233 metabolic markers to benign prostatic hyperplasia: Mendelian randomization and RNA-sequencing insights. [PDF]

J Chin Med Assoc
Zhou P, Zhu Z.
europepmc   +1 more source

5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management. [PDF]

Medicina (Kaunas)
Roidos C, Sountoulides P, Papathanasiou K, Symeonidis A, Mykoniatis I.   +4 more
europepmc   +1 more source

Exploring Sulpiride as an Alternative to Testosterone Propionate for Inducing Benign Prostatic Hyperplasia in Rodent Models. [PDF]

Toxics
Owumi S, Pius EM, Abdulganiyu HA, Alabi IO, Eso VO, Sanusi AA, Owolabi OM, Arunsi UO, Babalola JO, Otunla MT, Akomolafe AP, Olapade-Olaopa EO, Oyelere AK, Ogunwobi OO, Amadi CM.   +14 more
europepmc   +1 more source

AI-based modeling of treatment decisions in benign prostatic hyperplasia: a transformer-based comparative study. [PDF]

BMC Med Inform Decis Mak
Alshraideh M, Alshraideh B, Alshraideh A, Alfayoumi B, HebaAlshraideh.   +4 more
europepmc   +1 more source

Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling. [PDF]

Sci Rep
Alomari G, Al-Trad B, Qar J, Tahat L, Abu Haija Y, Al-Najjar A, Albokhadaim I, Shousha S, Alameen AO, Shukry M.   +9 more
europepmc   +1 more source